Clinical trial · Interventional
Evaluation of Intravenous Lidocaine and Time to Regression of the Sensory Block After Spinal Anesthesia (ELSA Trial)
Intravenous Lidocaine and Time to Regression of the Sensory Block After Spinal Anesthesia With Isobaric Bupivacaine in Patients Undergoing Surgery to Treat Skin and Soft Tissue Tumors of the Lower Limbs
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The use of intravenous lidocaine in continuous infusion in the perioperative period is associated with a reduction in postoperative pain scores, opioid use, incidence of nausea and vomiting, among other favorable outcomes. However, this therapeutic intervention has not yet been adequately evaluated by clinical trials when associated with regional anesthesia. The aim of this study is to evaluate whether the use of intravenous lidocaine in continuous infusion during spinal anesthesia with isobaric bupivacaine alters the time to regression of sensory block in patients undergoing surgical procedures for the treatment of bone and connective tissue tumor surgeries. This will be a triple-blind randomized trial. The sample size estimated was 66 patients. The study will include all patients who meet the pre-established inclusion and exclusion criteria, choose to participate, and agree with the Informed Consent Form. The main anesthetic technique will be spinal anesthesia with 13 mg of isobaric bupivacaine. Patients will be allocated in two groups in a blindly after randomization: Group S (lidocaine 0.75mg.kg-1 in bolus followed by infusion of saline solution) and Group L (lidocaine 1.5 mg.kg-1 followed by continuous infusion of lidocaine solution at 2 mg.kg-1.h-1). The primary outcome will be the time to T12 regression of the sensory block. Will also be evaluated: time to regression of the motor block, most rostral dermatome achieved by the sensory block, time to two-segment regression oh the sensory block, propofol dose in the operating room, postoperative pain score at rest, pain at movement score, quality of recovery, use of opioids in the postoperative period, nausea or vomiting, dizziness, shivering, arrhythmias, hypotension, urinary retention, and length of stay. The records will be assigned to the RedCap database. The data will be extracted without identification of the allocation groups for the R software and the groups will be revealed to the researcher after the end of the statistical analysis to write the summary of the results. The results will be submitted to scientific journals afterward.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Anesthesia | — | UNRESOLVED | — |
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Lidocaine IV | Drug | — | UNRESOLVED |
| Saline | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Group L (Lidocaine)
- description
- Lidocaine bolus 1.5 mg.kg-1 intravenous before the onset of lidocaine infusion Lidocaine 2mg.kg-1.h-1
- interventionNames
- Drug: Lidocaine IV
- type
- PLACEBO_COMPARATOR
- label
- Group S (saline solution)
- description
- Lidocaine bolus 0.75 mg.kg-1 intravenous before the onset of saline infusion Saline solution infusion
- interventionNames
- Drug: Saline
Primary outcomes (1)
- measure
- Time to T12 regression of the sensory block
- timeFrame
- Period: Day 0 postoperative
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 85 Years
Show eligibility criteria text
Inclusion Criteria: * Age between 18 and 85 years-old * The American Society of Anesthesiologists (ASA) physical status classification from I to III * To be submitted to: * \- Spinal Anesthesia * \- For surgeries performed by the Bone and Connective Tissue (TOC) service * \- Involving lower limbs and inguinal region requiring sensory block level up to the T12 dermatome (except for larger amputations and bone resections) * \- Expected duration of less than 120 minutes * \- In supine position * That they voluntarily decide to participate in the study Exclusion Criteria: * Coagulation disorder that prevents the execution of the blockade: * \- International normalized ratio for prothrombin (INR) time and activity \> 1.5 * \- Activated partial thromboplastin time ratio (PTTa) \>1.5 * \- Use of enoxaparin up to 40mg/day less than 12h before the procedure * \- Use of enoxaparin above 40mg/day less than 24hours before the procedure * \- Use of oral anticoagulant or platelet aggregation inhibitors in a lower interval than recommended for spinal block * \- Other coagulation disorders that prevent spinal anesthesia * Moderate or severe left ventricular systolic dysfunction (defined by the presence of left ventricle ejection fraction below 40%) * Sinus bradycardia (FC \< 50 beats per minute) * Relevant cardiac conduction system disorders (e.g. atrium ventricular block greater than first-degree, Wolf-Parkinson-White syndrome) * Clinically significant arrhythmia (e.g. atrial fibrillation) * Body mass index (BMI) than \> 35 mg.kg-1 * Previous diagnosis of liver cirrhosis * Creatinine clearance \< 30 ml/min/1.73m2 estimated by the method of the Modification of Diet in Renal Disease (MDRD) study group * Infection at the site of lumbar puncture * Previous spinal surgery * Allergy to local anesthetics amino-amides * Difficulty in communication, understanding or cognitive deficit that prevents adequate oral response to study the study forms * Pre-existing neurological lesion in topography to be evaluated motor block * Documented or suspected spinal or central nervous system metastasis * Regular use of strong opioids at a dose equal or greater than 60 mg of oral morphine equivalents per day * Desire to withdraw from the study at any time of its execution
References
Publications (22)
- BACKGROUNDMiller RD. Miller's Anesthesia. 7th ed. Phyladelphia: Churchill Livingstone/Elsevier; 2010.
- BACKGROUNDImbelloni LE, Moreira AD, Gaspar FC, Gouveia MA, Cordeiro JA. Assessment of the densities of local anesthetics and their combination with adjuvants: an experimental study. Rev Bras Anestesiol. 2009 Mar-Apr;59(2):154-65. doi: 10.1590/s0034-70942009000200003. English, Portuguese. PMID 19488527
- BACKGROUNDLui AC, Polis TZ, Cicutti NJ. Densities of cerebrospinal fluid and spinal anaesthetic solutions in surgical patients at body temperature. Can J Anaesth. 1998 Apr;45(4):297-303. doi: 10.1007/BF03012018. PMID 9597201
- BACKGROUNDBeloeil H. Opioid-free anesthesia. Best Pract Res Clin Anaesthesiol. 2019 Sep;33(3):353-360. doi: 10.1016/j.bpa.2019.09.002. Epub 2019 Sep 26. PMID 31785720
- BACKGROUNDBlaudszun G, Lysakowski C, Elia N, Tramer MR. Effect of perioperative systemic alpha2 agonists on postoperative morphine consumption and pain intensity: systematic review and meta-analysis of randomized controlled trials. Anesthesiology. 2012 Jun;116(6):1312-22. doi: 10.1097/ALN.0b013e31825681cb. PMID 22546966
- BACKGROUNDGelineau AM, King MR, Ladha KS, Burns SM, Houle T, Anderson TA. Intraoperative Esmolol as an Adjunct for Perioperative Opioid and Postoperative Pain Reduction: A Systematic Review, Meta-analysis, and Meta-regression. Anesth Analg. 2018 Mar;126(3):1035-1049. doi: 10.1213/ANE.0000000000002469. PMID 29028742
- BACKGROUNDNg KT, Yap JLL, Izham IN, Teoh WY, Kwok PE, Koh WJ. The effect of intravenous magnesium on postoperative morphine consumption in noncardiac surgery: A systematic review and meta-analysis with trial sequential analysis. Eur J Anaesthesiol. 2020 Mar;37(3):212-223. doi: 10.1097/EJA.0000000000001164. PMID 31977626